This finding is consistent with a previous study showing MLL4 deficiency sensitizes tumors to immune checkpoint blockade (28), and that MLL4 mutation status (especially truncation mutations) in cancer patients may predict response to immunotherapy and influence patient stratification and decision making. Here, KMT2D is linked to cancer.